Literature DB >> 7965151

Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors.

M J Gelfand1, A H Elgazzar, V M Kriss, P R Masters, G J Golsch.   

Abstract

UNLABELLED: Iodine-123-metaiodobenzylguanidine (MIBG) SPECT was compared with 123I-MIBG planar imaging in 35 studies of 25 children with neural crest tumors.
METHODS: Iodine-123-MIBG (0.070-0.140 mCi/kg intravenously) was followed at 24 hr by wholebody planar imaging and triple-detector, high-resolution thoraco-abdominal SPECT. At 48 hr, thoracoabdominal planar imaging was performed whenever a high-tissue background or gut activity interfered with the interpretation of the 24-hr planar images. SPECT views included a cine loop presentation of multiple volume-rendered projections. Two reviewers enumerated the number of abnormal sites on the planar and SPECT studies and rated the certainty of interpretation for each study on a scale from 0.1 (low certainty) to 1.0 (high).
RESULTS: Abnormal uptake was noted on planar or SPECT imaging in 13 studies (seven patients). The average number of abnormal sites detected per study for all 35 studies was 2.7 for planar imaging and 2.9 for SPECT (p = not significant) (and 7.2 and 8.4 for planar and SPECT, respectively, for the 13 abnormal studies.) The certainty ratings for all 35 studies were 0.74 for planar studies, 0.82 for SPECT (p = 0.05, chi-square, compared with planar) and 0.86 for planar and SPECT combined (p = 0.01 compared with planar alone). On volume-rendered images, gut activity was seen as diffuse and/or linear intraluminal activity.
CONCLUSION: When 123I-MIBG SPECT is used, the number of lesions detected is not increased, but there is a significant improvement in the certainty of interpretation over planar imaging.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965151

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  8 in total

1.  Guidelines for radioiodinated MIBG scintigraphy in children.

Authors:  Pierre Olivier; Paula Colarinha; Jure Fettich; Sibylle Fischer; Jörgen Frökier; Francesco Giammarile; Isky Gordon; Klaus Hahn; Levent Kabasakal; Mike Mann; Mercedes Mitjavila; Amy Piepsz; Ute Porn; Rune Sixt; Jeannette van Velzen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-03-26       Impact factor: 9.236

Review 2.  Where are we with nuclear medicine in pediatrics?

Authors:  H R Nadel
Journal:  Eur J Nucl Med       Date:  1995-12

3.  Does the Incremental Value of 123I-Metaiodobenzylguanidine SPECT/CT over Planar Imaging Justify the Increase in Radiation Exposure?

Authors:  Dorra Ben-Sellem; Naima Ben-Rejeb
Journal:  Nucl Med Mol Imaging       Date:  2021-07-07

Review 4.  Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force.

Authors:  K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn
Journal:  Br J Cancer       Date:  2010-04-27       Impact factor: 7.640

Review 5.  Dosimetry of FDG PET/CT and other molecular imaging applications in pediatric patients.

Authors:  Michael J Gelfand
Journal:  Pediatr Radiol       Date:  2008-12-16

Review 6.  123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma.

Authors:  Gitta Bleeker; Godelieve A M Tytgat; Judit A Adam; Huib N Caron; Leontien C M Kremer; Lotty Hooft; Elvira C van Dalen
Journal:  Cochrane Database Syst Rev       Date:  2015-09-29

7.  Imaging in neuroblastoma: An update.

Authors:  Seema A Kembhavi; Sneha Shah; Venkatesh Rangarajan; Sajid Qureshi; Palak Popat; Purna Kurkure
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

8.  Value of SPECT/CT in Diagnostic I-131 MIBG Scintigraphy in Patients with Neuroblastoma.

Authors:  Daris Theerakulpisut; Yutapong Raruenrom; Nantaporn Wongsurawat; Charoonsak Somboonporn
Journal:  Nucl Med Mol Imaging       Date:  2018-07-16
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.